GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting November 6, 2023
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023 August 3, 2023
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update March 30, 2023
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market December 30, 2022
